User:Cralster/sandbox

Feraccru®

Feraccru® (Ferric Maltol) is a stable, non-salt, oral formulation of ferric iron, which has a novel mechanism of action compared to salt-based oral iron therapies.

Understanding iron deficiency

ID is one of the most common and widespread nutritional disorder in the world, and is defined as a condition in which there are no mobilisable iron stores and signs and/or symptoms of a compromised supply of iron to tissues. The more severe stages of ID are associated with anaemia, therefore iron deficiency anaemia (IDA) is regarded as a subset of iron deficiency and is used to screen for ID. The terms anaemia, ID, and IDA are sometimes used interchangeably. There are, however, mild-to-moderate forms of ID in which, although anaemia is absent, tissues are still functionally impaired.

ID prevalence in adults is 4-12% dependent on age and sex,2 whereas IDA has a prevalence 2–5% among adult men and postmenopausal women.

Feraccru is different from other iron treatments

Feraccru contains the ferric form of iron (Fe3+). Most oral iron treatments contain the ferrous form of iron (Fe2+). Feraccru creates a stable complex for delivery by tightly binding ferric iron to three maltol molecules. It’s this unique structure that makes it an efficacious, well‑tolerated oral iron treatment for adult patients with ID.

Feraccru is indicated for the treatment of iron deficiency (ID) in adults.

Each capsule contains 30 mg iron (as ferric maltol)1

Excipient(s) with known effect: Each capsule contains 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110)

Key benefits of Feraccru:

Feraccru rapidly relieves IDA Feraccru is well tolerated Feraccru’s stable delivery method encourages efficient iron absorption, minimises iron accumulation and limits harmful free-radical generation in the gut

To read the Feraccru SmPC for Europe go to: https://www.medicines.org.uk/emc/medicine/31722